Last reviewed · How we verify

Britannia Pharmaceuticals Ltd. — Portfolio Competitive Intelligence Brief

Britannia Pharmaceuticals Ltd. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
  2. Beth Israel Deaconess Medical Center · 1 shared drug class
  3. Desitin Arzneimittel GmbH · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Intec Pharma Ltd. · 1 shared drug class
  6. Leiden University Medical Center · 1 shared drug class
  7. Ludwig-Maximilians - University of Munich · 1 shared drug class
  8. Axxonis Pharma AG · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Britannia Pharmaceuticals Ltd.:

Cite this brief

Drug Landscape (2026). Britannia Pharmaceuticals Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/britannia-pharmaceuticals-ltd. Accessed 2026-05-16.

Related